

ASX Announcement

29 May 2025

Results of Extraordinary General Meeting

Melbourne, Australia – 29 May 2025: Pancreatic cancer treatment device company **OncoSil Medical Limited (ASX:OSL) (“OncoSil” or “the Company”)**, advises that all resolutions considered at the Extraordinary General Meeting held today were carried by poll.

In accordance with ASX Listing rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, details of the proxies received and votes cast in respect of each resolution are attached.

Nathan Jong
Company Secretary

OncoSil Medical Ltd
Extraordinary General Meeting
Thursday, 29 May 2025
Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result	If s250U applies
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried	
1. SHARE CONSOLIDATION	Ordinary	838,804,559 73.37%	293,314,422 25.66%	11,148,798 0.98%	304,531	859,122,571 74.55%	293,314,422 25.45%	304,531	Carried	N/A
2. APPROVAL OF FUTURE ISSUE OF SHARES	Ordinary	943,151,595 82.50%	189,673,677 16.59%	10,439,538 0.91%	307,500	962,760,347 83.54%	189,673,677 16.46%	307,500	Carried	N/A
3. ISSUE OF OPTIONS TO LEL SMITS	Ordinary	1,009,352,771 88.34%	114,463,454 10.02%	18,825,719 1.65%	930,366	1,030,129,401 90.00%	114,463,454 10.00%	930,366	Carried	N/A
4. RATIFICATION OF PRIOR ISSUE OF OPTIONS	Ordinary	938,252,620 82.34%	184,423,935 16.18%	16,807,688 1.48%	4,088,067	962,278,611 83.92%	184,423,935 16.08%	6,038,978	Carried	N/A
5. APPROVAL OF OMNIBUS PLAN	Ordinary	924,253,560 81.13%	198,206,377 17.40%	16,802,688 1.47%	4,309,685	941,056,248 82.60%	198,206,377 17.40%	6,260,596	Carried	N/A

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.